Rosie O’Donnell‘s ability to recite the Primatene Mist commercial from her childhood really made Bill Gates suspicious. At least that was the reason O’Donnell believes he kept pestering her about ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Back when Rosie O’Donnell was just starting out as a talk show host, she was also coveted for a research project by Bill Gates. According to the actress and host, the billionaire’s team would call ...

Aug 18 (Reuters) - Temasek-backed Milky Mist Dairy Food (MILY.NS), opens new tab rose roughly 30% in its Indian trading debut on Tuesday as investors bet on growing demand for ‌value-added dairy ...

A proposed rule would require companies to notify the agency about ingredients they are using, but it is unclear if the agency has the resources to vet them all. By Alice Callahan and Dani Blum The ...

Rosie O’Donnell once found herself on the radar of Bill Gates’ research team for a surprisingly personal reason. The billionaire’s team reportedly contacted the talk show host repeatedly during the ...

The Trump administration said it’s taking first steps in strengthening rules over ingredients food companies have long added to their products with minimal oversight. Under a proposed rule announced ...

Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portfolio and new product introductions.

Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity ...

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 5.4% year on year to $183.9 million. Its non-GAAP profit ...

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported in Q2 CY2026, with sales up 5.4% year on year to $183.9 million. Its non-GAAP profit of $0.91 per share was 48.3% above analysts’ ...